Needham Assigns a Buy Rating on Stoke Therapeutics (STOK)
Needham analyst Joseph Stringer assigned a Buy rating to Stoke Therapeutics (STOK) today and set a price target of $56.00. The company’s shares closed last Thursday at $52.00, close to its 52-week high of $53.82.
Stringer has an average return of 35.6% when recommending Stoke Therapeutics.
According to TipRanks.com, Stringer is ranked #3244 out of 7141 analysts.
Currently, the analyst consensus on Stoke Therapeutics is a Strong Buy with an average price target of $49.86.
See today’s analyst top recommended stocks >>
The company has a one-year high of $53.82 and a one-year low of $15.82. Currently, Stoke Therapeutics has an average volume of 120.8K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STOK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.